Antigenics Inc. (NASDAQ: AGEN) reported results for the quarter ended September 30, 2008.

Antigenics Inc. (NASDAQ: AGEN) today announced that Garo Armen, Ph.D., the company's chairman and chief executive officer, will present at the Rodman and Renshaw 10th Annual Healthcare Conference at the Palace Hotel in New York on Monday, November 10, 2008 at 12:25 p.m. Eastern Time. Dr.

Antigenics, a biotechnology company, has submitted a marketing authorization application to the European Medicines Agency requesting approval for Oncophage in earlier-stage, localized renal cell carcinoma under the conditional authorization provision.

Antigenics Inc. (NASDAQ: AGEN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) requesting approval for Oncophage(R) in earlier-stage, localized renal cell carcinoma (kidney cancer) under the conditional authorization provision.

Antigenics, a biotechnology company, has announced that the FDA has granted the necessary permission to allow for the export of Oncophage to Russia.